Customer Logins

Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.

Customer Logins

Life Sciences Consulting

Market access, pricing, forecasting, and value of prevention and treatment

IHS Markit offers tailored solutions for life sciences corporate, government, financial sector and industry association clients. We work with you to optimize product positioning and develop value estimates, strategize innovative approaches and processes, streamline knowledge management, develop bespoke models and analytics, and identify opportunities and mitigate risk

With unique data , analytics, and tools at our fingertips, we help you to:

  • Monitor and quantify events in the global pricing and reimbursement landscape
  • Set market access strategies
  • Model the health and economic impact of disease intervention, and much more.

How our clients use our services

Government planners and policy makers: National, state, and local
  • Identify gaps between health needs and available resources to target key issues and prioritize opportunities for change
  • Evaluate potential impact of population health and disease prevention strategies
  • Simulate health policy impacts on payments and the local economy
  • Understand the health-related impacts of policies and programs regarding pollution, transportation, and sustainability
Hospitals and health systems
  • Plan your operating service line growth strategy based on projected population health, service demand, and associated infrastructure needs
  • Forecast future demand for physicians and other health professions by care setting
  • Provide a fact-based understanding of local population healthcare needs to support community health needs assessments and future hospital opportunities
Pharmaceutical and medical device manufacturers
  • Strengthen the value proposition of products by linking it to cost savings
  • Develop strategy for international pricing and growth
  • Quantify future market demand
Associations and foundations
  • Quantify the clinical and economic value proposition of healthcare interventions
  • Inform health workforce strategy
  • Forecast prevalence of disease and market implications
Business decision makers
  • Quantify health impacts of sustainability policies and practices
  • Evaluate or compare wellness programs regarding impact on the bottom line

Research publications

Experts

Timothy Dall

​A trained health economist, he brings more than 20 years of experience conducting research and policy analysis in the areas of health economics and outcomes, health workforce, health care delivery and disease cost and prevention. His work applies economic theory, statistical and econometric analysis, cost/benefit analysis, program evaluation, and computer modeling skills. Much of his work uses microsimulation modeling to address complex forecasting and policy issues. Applied research conducted by Mr. Dall supports strategic planning and advocacy work for governments, associations, life sciences companies, payers, provider networks, and non-profit organizations. He has published widely in peer-reviewed journals. Mr. Dall earned his Master of Science in Labor Economics at the University of Wisconsin-Madison, US, and his Bachelor of Science in Economics from Utah State University, Logan, Utah, US.

View Profile

Gustav Ando

Mr. Ando oversees the development of IHS Markit's global healthcare outlook analysis that focuses on market access, cost of healthcare and new treatment advances as well as coordinating its ongoing thinking on COVID-19. He heads the research and data teams that produce daily analysis, risk assessment and critical data for the pharmaceutical industry, as well as the consulting team that focuses on disease prevention, workforce and demand healthcare microsimulation models. With more than 15 years of experience in the industry, he is a regular speaker at conferences and is frequently cited by major media publications and national radio and television programs. He is the author and podium presenter of research at numerous academic conferences such as ISPOR. Mr Ando also oversees our global comparative industry group which provide critical long-term forecast perspectives across all industries around the world, as well as our specialised global constructrion group. Mr. Ando holds a postgraduate degree from the University of Uppsala, Sweden, and an undergraduate degree from the University of Durham in the United Kingdom.

View Profile

Cameron Lockwood

Mr. Lockwood collaborates with colleagues across Life Sciences and other teams to look at information and data rich solutions addressing client needs in the healthcare industry. Across diverse geographies, his work encompasses pricing and reimbursement, market access and policy-related topics relevant to pharmaceuticals, medical devices and other healthcare technologies. He oversees production of the “International Reference Pricing Guidebook,” IHS Markit’s comprehensive syndicated research offering detailing the nuances of IRP policy across 60+ countries. Cameron Lockwood joined the Life Sciences team in the London office in 2011, supporting the multiclient studies practice and he is currently based in the San Francisco Bay Area. Previously, he worked in the fields of healthcare communications and business intelligence. In addition to a graduate diploma in statistics through the University of Sheffield, he holds a Bachelor of Science in molecular biology from the University of Manchester, United Kingdom.

View Profile

Floriane Reinaud

Ms. Reinaud manages the PharmOnline International (POLI) and therapeutic module databases. She oversees the global information management team that manages the pharmaceutical pricing, cost and reimbursement data, including product positioning, client support, associated research and consulting projects. Ms. Reinaud is an authority on the impact of P&R policies, market access strategies and specialist topics, including risk-sharing agreements, orphan drugs, generics and biosimilars. She joined the company in 2007 and has over ten years of experience in pricing and reimbursement. Floriane Reinaud studied biology and holds an Master of Science in biochemistry, as well as Master of Science in healthcare marketing. She co-authored a peer-reviewed article that was published in The Journal of Biological Biochemistry. She is fluent in French and English.

View Profile

Milena Izmirlieva

Ms. Izmirlieva heads the Life Sciences research team which comprises senior analysts, analysts and health economists covering developed and emerging markets worldwide. Since joining IHS Markit's Global Insight in 2003 as a research analyst in the Pharma Practice for Western European and Central and Eastern European markets, she has developed extensive knowledge of the healthcare systems and pharmaceutical markets of numerous countries in Europe, North America and various emerging markets. Her main areas of research interest are pricing and reimbursement and market access for originator drugs, the market dynamics for biosimilars and generics, heath system efficiency indicators and health system capacity, and forecasting of healthcare spending and pharmaceutical sales. Before joining IHS Markit, she worked in healthcare marketing communications for the EURO RSCG group in New York, US, and Sofia, Bulgaria, where she specialised in pharmaceutical and medical device companies. She holds a Master of Science degree in Communication with a focus on Science Writing from Iowa State University and a joint BA degree in Journalism and Mass Communication and International Relations from the American University in Bulgaria, and is in the process of completing a Master of Science degree in Health Economics, Policy and Management at the London School of Economics. Ms. Izmirlieva is a regular speaker at pharmaceutical conferences and is often interviewed about pharmaceutical-related issues in the media. She frequently presents peer-reviewed research at ISPOR and has a strong interest in pharmaceutical pricing and reimbursement developments and cost-containment strategies (including international reference pricing). Ms. Izmirlieva is a Fulbright scholarship recipient and member of the following honour societies: Phi Kappa Phi, Alfa Delta Sigma, and Kappa Tau Alfa.​

View Profile

Dr. Mark Morgan, Ph.D.

Dr. Morgan has dedicated more than two decades to consulting in specialty chemicals, process technology and industrial biotechnology. In add

View Profile

Follow us on Twitter

{}

Explore

Filter Sort